Duality of purpose: Participant and parent understanding of the purpose of genomic tumor profiling research among children and young adults with solid tumors.
暂无分享,去创建一个
Jonathan M Marron | B. Crompton | A. Cronin | K. Janeway | J. Mack | S. DuBois | A. Kim | J. Glade-Bender | Stephanie C. Meyer | Julia L. Glade-Bender | AeRang Kim
[1] Jessica L. Davis,et al. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. , 2018, The Lancet. Oncology.
[2] Jonathan M Marron,et al. Intended and unintended consequences: Ethics, communication, and prognostic disclosure in pediatric oncology , 2018, Cancer.
[3] W. Chung,et al. Whole-Genome and Whole-Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations. , 2018, JCO precision oncology.
[4] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[5] P. Varlet,et al. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial , 2017, Clinical Cancer Research.
[6] Donavan T. Cheng,et al. Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.
[7] S. Roberts,et al. A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long‐term progression‐free survival of patients with resistant neuroblastoma , 2017, International journal of cancer.
[8] J. Kimmelman. Is Participation in Cancer Phase I Trials Really Therapeutic? , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Laura A. Levit,et al. Reaffirming and Clarifying the American Society of Clinical Oncology’s Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Jonathan M Marron,et al. Patient/parent perspectives on genomic tumor profiling of pediatric solid tumors: The Individualized Cancer Therapy (iCat) experience , 2016, Pediatric blood & cancer.
[11] Tao Wang,et al. Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors. , 2016, JAMA oncology.
[12] B. Crompton,et al. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. , 2016, JAMA oncology.
[13] J. Khan,et al. MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research , 2016, Clinical Cancer Research.
[14] L. Garraway,et al. Oncologists' and Cancer Patients' Views on Whole-Exome Sequencing and Incidental Findings: Results from The CanSeq Study , 2016, Genetics in Medicine.
[15] G. Leverger,et al. Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. , 2015, JAMA oncology.
[16] Nallasivam Palanisamy,et al. Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. , 2015, JAMA.
[17] W. Chung,et al. Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research , 2015, Pediatric blood & cancer.
[18] J. Mack,et al. Parental Hope for Children With Advanced Cancer , 2015, Pediatrics.
[19] Laura A. Levit,et al. American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Mick P Couper,et al. Design, methods, and participant characteristics of the Impact of Personal Genomics (PGen) Study, a prospective cohort study of direct-to-consumer personal genomic testing customers , 2014, Genome Medicine.
[21] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[22] Victoria A. Miller,et al. Hope and persuasion by physicians during informed consent. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Kelvin K. W. Chan,et al. Genomic testing in cancer: Patient knowledge, attitudes, and expectations , 2014, Cancer.
[24] S. Gabriel,et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.
[25] Fiona A Miller,et al. Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care , 2013, European Journal of Human Genetics.
[26] K. Weinfurt,et al. Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] D. Drotar,et al. Communicating and understanding the purpose of pediatric phase I cancer trials. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] Colleen Lewis,et al. Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials , 2012, Cancer.
[29] P. Appelbaum,et al. Therapeutic misconception in research subjects: Development and validation of a measure , 2012, Clinical trials.
[30] M. Baccarani,et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). , 2012, Blood.
[31] E. Cook,et al. Outcomes of informed consent among parents of children in cancer clinical trials , 2011, Pediatric blood & cancer.
[32] B. Bernhardt,et al. Motivations and Perceptions of Early Adopters of Personalized Genomics: Perspectives from Research Participants , 2011, Public Health Genomics.
[33] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[34] C. Grady,et al. Clinical Trials and Medical Care: Defining the Therapeutic Misconception , 2007, PLoS medicine.
[35] P. Appelbaum,et al. Therapeutic misconception in clinical research: frequency and risk factors. , 2004, IRB.
[36] Paul S Appelbaum,et al. The Therapeutic Misconception: Problems and Solutions , 2002, Medical care.
[37] Steven Joffe,et al. Quality of informed consent in cancer clinical trials: a cross-sectional survey , 2001, The Lancet.
[38] C. Sawyers,et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.
[39] E F Cook,et al. Quality of informed consent: a new measure of understanding among research subjects. , 2001, Journal of the National Cancer Institute.
[40] Thomas J. Smith,et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] N. Magné,et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] P. Appelbaum,et al. The Therapeutic Misconception , 2008 .
[43] Genetic counseling: an indispensable step in the genetic testing process. , 2008, Journal of Oncology Practice.
[44] L. Furr,et al. The Genetic Knowledge Index: developing a standard measure of genetic knowledge. , 1999, Genetic testing.